Detection of Micro-RNA 511-5p in psoriasis patients and its correlation with disease severity
Naguib, R., Anan, M., Abd El Rahman,, S., Mamdouh, N. (2025). Detection of Micro-RNA 511-5p in psoriasis patients and its correlation with disease severity. EKB Journal Management System, 6(3), 87-103. doi: 10.21608/ejmr.2025.331835.1725
Rehab Mohamed Naguib; Mera Mohamed Galal Anan; Shymaa Kamal El Din Abd El Rahman,; Nancy Magdy Mamdouh. "Detection of Micro-RNA 511-5p in psoriasis patients and its correlation with disease severity". EKB Journal Management System, 6, 3, 2025, 87-103. doi: 10.21608/ejmr.2025.331835.1725
Naguib, R., Anan, M., Abd El Rahman,, S., Mamdouh, N. (2025). 'Detection of Micro-RNA 511-5p in psoriasis patients and its correlation with disease severity', EKB Journal Management System, 6(3), pp. 87-103. doi: 10.21608/ejmr.2025.331835.1725
Naguib, R., Anan, M., Abd El Rahman,, S., Mamdouh, N. Detection of Micro-RNA 511-5p in psoriasis patients and its correlation with disease severity. EKB Journal Management System, 2025; 6(3): 87-103. doi: 10.21608/ejmr.2025.331835.1725

Detection of Micro-RNA 511-5p in psoriasis patients and its correlation with disease severity

Egyptian Journal of Medical Research
Volume 6, Issue 3, July 2025, Pages 87-103    PDF (433.36 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2025.331835.1725
Authors
Rehab Mohamed Naguib1; Mera Mohamed Galal Anan* 2; Shymaa Kamal El Din Abd El Rahman,3; Nancy Magdy Mamdouh4
1Assistant professor of dermatology and venerology, Faculty of Medicine, Beni-suef University
2Lecturer of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University
3Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Beni- Suef University
4Lecturer of dermatology and venerology, Faculty of Medicine, Beni-suef University
Abstract
Background: A chronic inflammatory skin condition, psoriasis affects around 2-4% of people globally. The cutaneous manifestations of psoriasis are variable. MicroRNA are short, single-stranded, noncoding RNA molecules. People with psoriasis have been shown to express several miRNAs differently in their blood or psoriatic skin. Aim: In the current study we aimed to detect microRNA 511-5p in serum samples of psoriasis patients, correlate its presence to disease severity and compare its level between patients and control subjects. Methods: The research involved 30 patients who had psoriasis and 30 control individuals in Beni-Suef University hospital. Psoriasis diagnosis was confirmed according to the typical clinical presentation of psoriasis. The degree of psoriasis severity was evaluated using PASI score. Three cm peripheral blood were taken from all patients and control subjects. Levels of microRNA 511-5p in serum samples were determined using reverse transcription PCR (rt-PCR). Results: A statistically significant difference was detected between miRNA 511-5p levels in cases and controls (p < 0.001). There is no statistically significant association was detected between miRNA 511-5p and PASI score (p = 0.162). the study revealed patients' ages and duration of illnesses had a positive correlation with baseline PASI. (p value = 0.04 and 0.001 respectively). Conclusion: we used qRT-PCR to examine Micro-RNA expression profile in psoriasis. MicroRNA 511-5p was significantly higher in psoriatic lesions, indicating that MicroRNA 511-5p might be used as a biomarker for psoriasis.
Keywords
psoriasis; Micro RNA; rt-PCR
References
1- Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci. 2020 Mar 1;21(5):1690. doi: 10.3390/ijms21051690. PMID: 32121574; PMCID: PMC7084606.

2- Banaszczyk K. Risankizumab in the treatment of psoriasis - literature review. Reumatologia. 2019;57(3):158-162. doi: 10.5114/reum.2019.86426. Epub 2019 Jun 28. PMID: 31462831; PMCID: PMC6710847.

3- Giampiero Girolomoni, Paolo Gisondi and Anna Chiara Fostini (2017): psoriasis and metabolic syndrome, J Eur Acad Dermatol Venereol ;36 (1),21-28.     

4- Okubo Y, Takahashi H, Hino R, Endo K, Kikuchi S, Ozeki Y. et al., Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study. Dermatol Ther (Heidelb). 2022 Jun;12(6):1469-1480. doi: 10.1007/s13555-022-00747-5. Epub 2022 Jun 11. PMID: 35689737; PMCID: PMC9209617. 

5- Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Moderate Psoriasis: A Proposed Definition. Actas Dermosifiliogr. 2017 Dec;108(10):911-917. English, Spanish. doi: 10.1016/j.ad.2017.07.002. Epub 2017 Aug 17. PMID: 28823420.  

6- Masalha M, Sidi Y, Avni D. The contribution of feedback loops between miRNAs, cytokines and growth factors to the pathogenesis of psoriasis. Exp Dermatol. 2018 Jun;27(6):603-610. doi: 10.1111/exd.13520. Epub 2018 Apr 10. PMID: 29479749. 

7- Solvin ÅØ, Chawla K, Olsen LC, Hegre SA, Danielsen K, Jenssen M, Furberg AS, Saunes M, Hveem K, Saetrom P, Løset M. MicroRNA profiling of psoriatic skin identifies 11 miRNAs associated with disease severity. Exp Dermatol. 2022 Apr;31(4):535-547. doi: 10.1111/exd.14497. Epub 2021 Nov 17. PMID: 34748247.

8- Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44. doi: 10.1159/000250839. PMID: 357213.

9- Chan YH.  Biostatistics102: Quantitative Data – Parametric & Non-parametric Tests. Singapore Medical Journal 2003a;44(8): 391-396.

10- Chan YH.  Biostatistics 103: Qualitative Data –Tests of Independence. Singapore Medical Journal 2003b;44(10): 498-503.

11- Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021 May;21(3):170-173. doi: 10.7861/clinmed.2021-0257. PMID: 34001566; PMCID: PMC8140694.

12- Ambros, V. The functions of animal microRNAs. Nature 431, 350–355 (2004).

13- Jiang NJ, Yin YN, Lin J, Li WY, Long DR, Mei L. MicroRNA-21 in gynecological cancers: From molecular pathogenesis to clinical significance. Pathol Res Pract. 2023 Aug;248:154630. doi: 10.1016/j.prp.2023.154630. Epub 2023 Jun 21. PMID: 37393665.

14- Mikrani, J. A., & Shrestha, A. Clinical and epidemiological features of psoriasis in patients visiting Lumbini Medical College. Journal of Lumbini Medical College. 2014; 2(1), 1-3.‏

15- Mohd Affandi A, Khan I, Ngah Saaya N. Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007-2016). Dermatol Res Pract. 2018 Apr 23;2018:4371471. doi: 10.1155/2018/4371471. PMID: 29849578; PMCID: PMC5937568.

16- Shalom G, Zisman D, Babaev M, Horev A, Tiosano S, Schonmann Y, et al. Psoriasis in Israel: demographic, epidemiology, and healthcare services utilization. Int J Dermatol. (2018) 57:1068–74. doi: 10.1111/ijd. 14130.

17- Anani HAA, Tawfeik AM, Maklad SS, Kamel AM, El-Said EE, Farag AS. Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients. Psoriasis (Auckl). 2020 May 21;10:13-21. doi: 10.2147/PTT.S241750. PMID: 32607312; PMCID: PMC7293414.

18- Bilgili ME, Yildiz H, Sarici G. Prevalence of skin diseases in a dermatology outpatient clinic in Turkey. A cross-sectional, retrospective study. J Dermatol Case Rep. 2013 Dec 30;7(4):108-12. doi: 10.3315/jdcr.2013.1156. PMID: 24421863; PMCID: PMC3888779..‏

19- Egeberg A, Sørensen JA, Gislason GH, Knop FK, Skov L. Incidence and Prognosis of Psoriasis and Psoriatic Arthritis in Patients Undergoing Bariatric Surgery. JAMA Surg. 2017 Apr 1;152(4):344-349. doi: 10.1001/jamasurg.2016.4610. Erratum in: JAMA Surg. 2018 Jul 1;153(7):692. doi: 10.1001/jamasurg.2018.0253. PMID: 28002543.

20- Ali G, Elsayed AK, Nandakumar M, Bashir M, Younis I, Abu Aqel Y, Memon B, Temanni R, Abubaker F, Taheri S, Abdelalim EM. Keratinocytes Derived from Patient-Specific Induced Pluripotent Stem Cells Recapitulate the Genetic Signature of Psoriasis Disease. Stem Cells Dev. 2020 Apr 1;29(7):383-400. doi: 10.1089/scd.2019.0150. Epub 2020 Mar 2. PMID: 31996098; PMCID: PMC7153648.

21- Genc M, Can M, Guven B, Cinar S, Buyukuysal C, Acikgoz B, Mungan AG, Acikgoz S. Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis. Indian J Clin Biochem. 2017 Mar;32(1):90-94. doi: 10.1007/s12291-016-0570-0. Epub 2016 May 6. PMID: 28149018; PMCID: PMC5247368.

22- El-Komy MHM, Mashaly H, Sayed KS, Hafez V, El-Mesidy MS, Said ER, Amer MA, AlOrbani AM, Saadi DG, El-Kalioby M, Eid RO, Azzazi Y, El Sayed H, Samir N, Salem MR, El Desouky ED, Zaher HAE, Rasheed H. Clinical and epidemiologic features of psoriasis patients in an Egyptian medical center. JAAD Int. 2020 Jul 21;1(2):81-90. doi: 10.1016/j.jdin.2020.06.002. PMID: 34409325; PMCID: PMC8362248.

23- Altobelli E, Petrocelli R, Marziliano C, Fargnoli MC, Maccarone M, Chimenti S, Peris K. Family history of psoriasis and age at disease onset in Italian patients with psoriasis. Br J Dermatol. 2007 Jun;156(6):1400-1. doi: 10.1111/j.1365-2133.2007.07906.x. PMID: 17535245.

24- Ammar-Khodja A, Benkaidali I, Bouadjar B, Serradj A, Titi A, Benchikhi H, Amal S, Hassam B, Sekkat A, Mernissi FZ, Mokhtar I, Dahoui R, Denguezli M, Doss N, Turki H. EPIMAG: International Cross-Sectional Epidemiological Psoriasis Study in the Maghreb. Dermatology. 2015;231(2):134-44. doi: 10.1159/000382123. Epub 2015 Jun 19. PMID: 26111474.

25- Chen K, Wang G, Jin H, Xu J, Zhu X, Zheng M, Gu H. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017 Jul 11;8(28):46381-46389. doi: 10.18632/oncotarget.18453. PMID: 28637026; PMCID: PMC5542274.

26- Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014 Apr 17;7:119-32. doi: 10.2147/CCID.S44843. PMID: 24790463; PMCID: PMC4000177.

27- Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015 Jan-Feb;90(1):9-20. doi: 10.1590/abd1806-4841.20153038. PMID: 25672294; PMCID: PMC4323693.

28- Fernandez-Torres RM, Paradela S, Fonseca E. Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. J Nutr Health Aging. 2012;16(6):586-91. doi: 10.1007/s12603-012-0009-0. PMID: 22660002.

29- Pierouli K, Papageorgiou L, Mitsis T, Papakonstantinou E, Diakou I, Leptidis S, Sigala M, Dragoumani K, Spandidos DA, Bacopoulou F, Chrousos GP, Goulielmos GΝ, Eliopoulos E, Vlachakis D. Role of microRNAs and long non‑coding RNAs in glucocorticoid signaling (Review). Int J Mol Med. 2022 Dec;50(6):147. doi: 10.3892/ijmm.2022.5203. Epub 2022 Nov 11. PMID: 36367164; PMCID: PMC9662139.

30- Puimège L, Van Hauwermeiren F, Steeland S, Van Ryckeghem S, Vandewalle J, Lodens S, Dejager L, Vandevyver S, Staelens J, Timmermans S, Vandenbroucke RE, Libert C. Glucocorticoid-induced microRNA-511 protects against TNF by down-regulating TNFR1. EMBO Mol Med. 2015 Aug;7(8):1004-17. doi: 10.15252/emmm.201405010. PMID: 25995337; PMCID: PMC4551340.

31- Alatas ET, Kara M, Dogan G, Akın Belli A. Blood microRNA expressions in patients with mild to moderate psoriasis and the relationship between microRNAs and psoriasis activity. An Bras Dermatol. 2020 Nov-Dec;95(6):702-707. doi: 10.1016/j.abd.2020.07.001. Epub 2020 Aug 5. PMID: 32811699; PMCID: PMC7672403.

 

Statistics
Article View: 99
PDF Download: 35